Sign in Create account
Sign in and upgrade to a paid plan to export financials as CSV.

Novartis India Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: NOVARTIND BSE: 500672
₹1919.00
▼ -5.10 (-0.27%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
68/100
Moderate
Valuation
2/100
Expensive
Momentum
51/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹4,738 Cr
PE (TTM)
48.4
Industry median 36.1 (152 companies)
Price to Book
5.8
PEG (TTM)
-9.5
Institutions holding %
1.52%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
53.4
Relative return vs Sector, qtr %
32.9
Free Cash Flow
₹46 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
16.62%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-5.13%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
5.64%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
16.62%
as of June 30, 2026
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
18.57%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
5.30
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.00
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
112.16
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
31.03%
as of June 30, 2026
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
41.64%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
36.92%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
9.52%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
15.71%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
11.39%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 7 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.00)
  • No Return on equity is 15% or more (11.4%)
  • Yes Net cash flow for the latest year is positive
  • No Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

2 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
-0.3%
Low 1910.0000 · High 2030.7000
1W return
-5.3%
Low 1905.0000 · High 2035.0000
1M return
23.5%
Low 1541.6000 · High 2588.8000
52W return
185.5%
Low 950.0000 · High 2588.8000
Lifetime High ₹2428.2000 (Sept. 10, 2026)
Lifetime Low ₹189.6000 (Oct. 23, 2001)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish3
Bearish3
5D
1945.0
10D
1964.5
20D
1923.6
50D
1766.2
100D
1566.2
200D
1181.5

Delivery and volume

Day avg. delivery
41.2%
Week avg. delivery
39.2%
Month avg. delivery
23.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

1953.23
Pivot
First resistance1996.47
Second resistance2073.93
Third resistance2117.17
First support1875.77
Second support1832.53
Third support1755.07
Day RSI52.4
Day MFI74.4
Day MACD73.34
Day MACD signal103.28

Beta

1M0.10
3M0.18
1Y-0.42
3Y-0.26

Price change analysis

↑ 23.5%
Over 1 Month
LowHigh
1541.602588.80
↑ 32.9%
Over 3 Months
LowHigh
1402.002588.80
↑ 185.5%
Over 6 Months
LowHigh
950.002588.80
↑ 185.5%
Over 1 Year
LowHigh
950.002588.80
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 48.4 (own history: 16.1–36.2)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹104 Cr
Net profit (June 30, 2026)
₹32 Cr
Basic EPS (June 30, 2026)
₹13.0500

Ranks #61 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter70.68%
  • Mutual funds0.69%
  • FII/FPI0.16%
  • Other DII0.67%
  • Public27.80%

Largest holders

NameCategoryShares %Shares
NOVARTIS AGPromoter70.6800%17450680
Atul LimitedPublic1.5200%374627

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 70.68% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.17% to 0.16% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 0.00% to 0.69% in Jun 2026 qtr

All shareholding details →

Deals (Bulk & Block)

All 15 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
7 Sep 2026 KARAN BHAGAT Bulk Buy 130,000 1670.5200 BSE
7 Sep 2026 KYRUSH INVESTMENTS Bulk Sell 130,000 1670.5000 BSE
16 Aug 2012 IDFC SMALL AND MIDCAP EQUITY SME FUND Bulk Sell 220,217 670.0200 BSE
29 Aug 2007 RELIANCE CAPITAL TRUSTEE CO.LTD. Bulk Buy 918,831 269.0000 BSE
29 Aug 2007 ICICI PRUDENTIAL ASSET MANAGEMENT CO.LTD. Bulk Sell 923,800 269.0200 BSE
23 Oct 2006 PRUDENTIAL ICICI AMC LTD Bulk Buy 877,000 435.0000 BSE
23 Oct 2006 T.ROWE PRICE INTERNATIONA Bulk Sell 877,221 435.0000 BSE
9 Jun 2006 TEMPLETON MUTUAL FUND AC Bulk Buy 209,440 422.0000 BSE
9 Jun 2006 ICICI BANK LTD TREASURY Bulk Sell 209,730 422.0000 BSE
17 Feb 2006 BIRLA SUNLIFE MUTUAL FUND Bulk Sell 436,221 594.8700 BSE

All bulk and block deals →

Dividends

Full dividend history →
Ex-dateSubjectPer share (₹)Record date
20 Jul 2023 Annual General Meeting/Dividend - Rs 10 Per Share/Special Dividend - Rs 37.50 Per Share 10.0000 —
20 Jul 2022 Dividend - Rs 10 Per Share 10.0000 —
17 Aug 2021 Dividend - Rs 10 Per Share 10.0000 —
2 Jul 2002 Dividend-150% — —
8 Oct 2001 Dividend-150% — —

Corporate Announcements

All 12 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
1 Oct 2026 Company Update Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association
1 Oct 2026 Company Update Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Change of Company Name
30 Sep 2026 Board Meeting Novartis India Ltd - 500672 - Board Meeting Intimation for Consideration And Approval Of The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.
30 Sep 2026 Insider Trading / SAST Novartis India Ltd - 500672 - Closure of Trading Window
25 Sep 2026 AGM/EGM Novartis India Ltd - 500672 - Intimation Of The Voting Results And The Scrutinizers Report For The 78Th Annual General Meeting Of The Company Held On Thursday, September 24, 2026.
21 Sep 2026 Company Update Novartis India Ltd - 500672 - Intimation Regarding The Newspaper Publication Made Regarding The Corrigendum Filed Dated September 18, 2026, For The Notice Of 78Th Annual General Meeting
18 Sep 2026 AGM/EGM Novartis India Ltd - 500672 - Corrigendum To The Notice Of 78Th Annual General Meeting
15 Sep 2026 Company Update Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Sep 2026 Company Update Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
11 Sep 2026 Company Update Novartis India Ltd - 500672 - Announcement under Regulation 30 (LODR)-Investor Presentation

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong net profit margin (31.0%)
  • Low financial leverage (Debt/Equity 0.00)
  • Comfortable interest coverage (112.2x)
  • Strong revenue growth YoY (18.6%)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (48.4) -- priced for continued strong execution

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Novartis India Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.